Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
2081-2100 of 2,120 trials

Ulcerative Colitis: RO7837195 Treatment Study

We are testing a new medication, RO7837195, for people with moderately to severely active ulcerative colitis. The study aims to see if it can help induce remission and how safe it is compared to a placebo.

Ulcerative Colitis>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Cemiplimab and Imiquimod for High-Risk Basal Cell Carcinoma

We are studying a combination of cemiplimab, imiquimod, and laser therapy for patients with high-risk cutaneous basal cell carcinoma. The goal is to evaluate safety and how well this treatment works before surgery.

Skin Cancer (Basal Cell Carcinoma)>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyOncology

Advanced Colorectal Cancer: OMTX705 Combination Therapy

We are studying a new drug, OMTX705, combined with regorafenib and tislelizumab for patients with advanced colorectal cancer. The goal is to evaluate its safety and effectiveness in those who have not responded to previous treatments.

Metastatic Colorectal Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Fluid Management in Critically Ill Adults: CRUSADERS Trial

We are studying whether reducing sodium and chloride in fluids helps critically ill adults have better health outcomes. This includes looking at effects on organ support needs and overall survival.

Healthy Participants>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrology

Tonsillectomy Pain Relief: Ropivacaine vs. Lidocaine

We are comparing two local anesthetics to see which one better reduces pain after tonsillectomy. This study aims to find the most effective option for managing postoperative discomfort.

Chronic Tonsillitis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOtolaryngology

Postoperative Pain Relief: High Dose Dexamethasone for Lung Surgery

We are studying whether a higher dose of Dexamethasone can reduce pain after video-assisted thoracoscopic surgery in patients who typically experience high pain. This trial compares a high dose to a standard lower dose to find the best pain management approach.

Lung Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngologyPulmonology

Botulinum Toxin Treatment: Patient Satisfaction Study

We are examining how satisfied patients are with split doses of botulinum toxin compared to a control group. The study also looks at the safety of this treatment over time.

Frown Lines6-12 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Darolutamide and Bipolar Androgen Therapy for Advanced Prostate Cancer

We are studying whether combining Darolutamide with bipolar androgen therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer compared to standard treatments.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Tulisokibart for Ankylosing Spondylitis

We are studying a new medication, tulisokibart, to see if it helps people with ankylosing spondylitis feel better compared to a placebo. The trial will assess improvements in pain, function, and overall quality of life.

Ankylosing Spondylitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Zelenectide Pevedotin for Advanced Non-small Cell Lung Cancer

We are studying a new treatment for patients with advanced or metastatic non-small cell lung cancer that has NECTIN4 amplification. The goal is to see how well it works and how safe it is for those who have already been treated.

Advanced Non-small Cell Lung Cancer1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Ovarian Cancer: COM701 Treatment Study

We are testing the safety and effectiveness of COM701 for patients with relapsed platinum-sensitive ovarian cancer. The study aims to see if it can help patients maintain their health without cancer progression.

Ovarian CancerRecurrent Ovarian Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Multiple Sclerosis: Subcutaneous vs. Intravenous Ublituximab

We are studying how a new subcutaneous injection of ublituximab compares to the intravenous version for people with relapsing multiple sclerosis. The goal is to evaluate its safety and effectiveness in managing the condition.

Relapsing Multiple SclerosisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurology

Non-Small Cell Lung Cancer: RMC-9805 and RMC-6236 Study

We are studying a new treatment combination for patients with RAS G12D-mutant non-small cell lung cancer. The trial will evaluate the safety and effectiveness of these drugs alongside other anticancer therapies.

Non-small Cell Lung Cancer3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Immunotherapy for Metastatic Colorectal and Prostate Cancer

We are studying a new treatment using patients' own immune cells to see if it is safe and tolerable for those with advanced colorectal or prostate cancer. The trial will help us understand how well this therapy works in these patients.

Locally Advanced or Metastatic Prostate CancerMetastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteGastroenterologyOncologyUrology

IVF/ICSI: Low Dose hCG Priming for Women with Diminished Ovarian Reserve

We are investigating whether low dose hCG priming can help women with diminished ovarian reserve retrieve more eggs during IVF/ICSI. This study aims to confirm earlier findings that suggest a significant increase in egg retrieval.

Infertility Due to Diminished Ovarian Reserve>2 yearsConfirmation phase (III)Standard MedicinesGynecology and Obstetrics

Acromegaly: ALXN2420 Treatment Study

We are studying whether the new drug ALXN2420 can help lower hormone levels and improve symptoms in adults with acromegaly when used with standard treatments. This trial compares ALXN2420 to a placebo to assess its effectiveness.

Acromegaly1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinology

Gastrointestinal Tumors: OncoGreen Imaging Study

We are testing a new imaging technique using OncoGreen to help surgeons better visualize tumors during surgery. This study is for patients with gastrointestinal tumors who are having surgery to remove their tumors.

Digestive System Tumors>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyInternal MedicineOncology

Atrial Fibrillation: Amiodarone Administration Study

We are comparing intravenous and enteral amiodarone in critically ill patients with new-onset atrial fibrillation. The goal is to see which method is more effective in restoring normal heart rhythm and improving overall health.

Atrial Fibrillation with Rapid Ventricular Response≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Chikungunya Vaccine: Effectiveness and Safety Study

We are evaluating how well the chikungunya vaccine works in preventing severe disease and hospitalizations in at-risk populations. This study aims to understand the vaccine's real-life impact on health outcomes.

Chikungunya1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Durvalumab for Limited Stage Small Cell Lung Cancer

We are studying the safety and effectiveness of durvalumab for patients with limited stage small cell lung cancer who have not progressed after chemoradiation therapy. This trial also looks at how the treatment affects quality of life and disease symptoms.

Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology